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The present study reports the activities of quercetin and its main circulating conjugates in man (quercetin-30-sulphate (Q30S) and quercetin-3-glu-
curonide (Q3G)) on in vivo angiogenesis induced by vascular endothelial growth factor (VEGF) and examines the effects of these molecules on
cultured endothelial cells. We found opposing effects of quercetin and its metabolites on angiogenesis. While quercetin and Q3G inhibited VEGF-
induced endothelial cell functions and angiogenesis, Q30S per se promoted endothelial cell proliferation and angiogenesis. The inhibitory effect
elicited by Q3G was linked to inhibition of extracellular signal-regulated kinases 1/2 (ERK1/2) phosphorylation elicited by VEGF. The activation
of endothelial cells by Q30S was associated to stimulation of VEGF receptor-2 and to downstream signalling activation (phosphatidylinositol-3
kinase/Akt and nitric oxide synthase pathways), ultimately responsible for ERK1/2 phosphorylation. These data indicate that the effects of circu-
lating quercetin conjugates on angiogenesis are different depending on the nature of the conjugate. Q3G and Q30S are the two major conjugates in
plasma, but their ratio is dependent on several factors, so that inhibition or activation of angiogenesis could be subtly shifted as a result of metab-
olism in vivo.
Angiogenesis: Quercetin: Quercetin conjugates: Microvascular endothelial cells: Proliferation: Mitogen-activated protein kinase
Quercetin, like other natural polyphenols, has attracted atten-
tion for the variety of biological properties that it appears to
possess. Predominant among these are the antioxidant and
antitumour activities that have been extensively described.
The antitumour effects of quercetin have been attributed to
its ability to interfere with tumour vascularisation through
inhibition of endothelial cell growth and migration
(Igura et al. 2001; Tan et al. 2003). At the molecular level,
quercetin reduces the expression and activity of matrix metal-
loproteinase-2, inhibits constitutive endothelial nitric oxide
synthase (Chiesi and Schwaller, 1995; Tan et al. 2003),
while other flavonoids have been demonstrated to inhibit vas-
cular endothelial growth factor (VEGF) induced endothelial
cell functions and signalling pathways (Kimura and Okuda,
2001; Hasebe et al. 2003; Lin et al. 2003; Bagli et al. 2004;
Tseng et al. 2004).
Most, but not all, epidemiological studies on quercetin have
shown that quercetin is protective against several different
types of cancer (Hertog et al. 1993; Knekt et al. 1996,
2002; Garcia-Closas et al. 1998, 1999; Neuhouser, 2004;
McCann et al. 2005). However, there are very few human
intervention studies on the chemopreventive effects of querce-
tin, and so the effect in man in vivo is not proven. In vitro,
many studies have used the aglycone of quercetin, which is
not found in significant amounts in vivo, and so it is important
to design in vitro experiments based on knowledge from in
vivo metabolism (Williamson, 2003).
Quercetin is mainly absorbed after deglycosylation, and is
rapidly metabolised to glucuronides and sulphates during
and after intestinal absorption, which therefore constitute the
major circulating forms of this polyphenol (Gee et al. 2000;
Day et al. 2001; O’Leary et al. 2001). Thus, although much
of the experimental work describes the pharmacodynamic
activities of quercetin, there is substantial evidence that the
molecule is very rapidly conjugated to form glucuronide and
sulphate derivatives, which in fact predominate in human
plasma after administration of quercetin-rich foods, while
only traces of the parent molecule may be found (Day et al.
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2001; O’Leary et al. 2001). Two studies have clearly shown
that the major quercetin conjugates are quercetin-30-sulphate
(Q30S) and quercetin-3-glucuronide (Q3G), but the ratio in
plasma in these studies was different. For one study,
Q30S . Q3G with a ratio of 3:1 after 90 min
(de Pascual-Teresa et al. 2004), and for the other,
Q30S , Q3G with a ratio of 1:1·6 after 90 min (Day et al.
2001). Therefore, any differences in biological activity of
quercetin conjugates would lead to an overall effect of querce-
tin depending on its metabolism. This metabolism would be
directly affected by the ratio of the enzymes UDP-glucurono-
syl transferase and sulphotransferase, which are both known to
be inducible and to vary between individuals (Burchell &
Coughtrie, 1997). The aim of the present study was to eluci-
date the activity of the two most abundant conjugates.
The present study reports the activities of quercetin and its
circulating conjugates, Q3G derived from intestinal metab-
olism and Q30S derived from liver metabolism, on angiogen-
esis induced by VEGF and examines the effects of these
molecules on microvascular endothelial cells.
Materials and methods
Angiogenesis in vivo: rabbit cornea assay
Angiogenesis was studied in the cornea of albino rabbits and
quantified by stereomicroscopic examination (Morbidelli et al.
2003; Bagli et al. 2004). Experiments have been performed in
accordance with the guidelines of the European Economic
Community for animal care and welfare (EEC Law no. 86/
609). Test substances were incorporated in slow-release pel-
lets prepared from a casting solution of ethynil-vinyl copoly-
mer (Elvax-40; DuPont-De Nemours, Wilmington, Delaware,
USA). Pellets were then implanted into micropockets surgi-
cally produced in the lower half of the eye of anaesthetised
New Zealand white rabbits (fifteen animals; Charles River,
Lecco, Italy). Compounds were delivered alone or in combi-
nation from one single micropocket. A concentration of
1mg/pellet polyphenol metabolites corresponded to a concen-
tration in the low micromolar range during the first 48 h after
pellet implant. Observation and quantification of the angio-
genic response were performed by a slit-lamp stereomicro-
scope. The potency of angiogenic activity was evaluated on
the basis of the number and growth rate of newly formed
capillaries, and an angiogenic score was calculated by the for-
mula (vessel density £ distance from limbus) as described in
Morbidelli & Ziche (2004).
Cell culture
Bovine post-capillary coronary venular endothelial cells
(CVEC) were obtained and cultured as previously described
(Ziche et al. 1997). Cells between passages 18 and 20 retain-
ing endothelial markers were used in the experiments.
Porcine aortic endothelial cells (PAEC) overexpressing vas-
cular endothelial growth factor receptor-2 (VEGFR-2; Walten-
berger et al. 1994) were maintained with Ham’s F-12 medium
supplemented with 10 % fetal calf serum (Hyclone, Inalco,
Milan, Italy) and 500mg/ml G418 sulphate antibiotic.
PAEC–VEGFR-2 cells were split weekly 1:3.
Cell proliferation
Cells resuspended in 10 % serum (1·5 £ 103) were seeded in
each well of ninety-six multiwell plates. After adherence
(5–6 h), the supernatant was replaced with medium containing
0·1 % bovine calf serum (BCS; Hyclone) for 24 h to synchro-
nise the cell cycle (Morbidelli et al. 2003). After 48 h incu-
bation with test substances in medium containing 0·1 %
BCS, cells were fixed in 100 % methanol and stained with
Diff-Quik (Mertz-Dade; Biomap, Milan, Italy). Total cell
number per well was counted at 100 £ magnification.
To determine possible toxicity of quercetin metabolites on
CVEC, the trypan blue exclusion test was used as previously
reported (Morbidelli et al. 2003).
Cell migration
Cell migration was assessed in forty-eight-well microchemo-
taxis chambers (NeuroProbe; Biomap) on a polycarbonate
filter, 8mm pore size, coated either with type I collagen or
fibronectin as reported (Morbidelli et al. 2003). A cell suspen-
sion containing 12 500 cells exposed to 1 nM-quercetin metab-
olites was added to the upper chamber of each well and VEGF
(20 ng/ml) to the lower one. Migrated cells were counted in
ten random fields per well at 400 £ magnification. Data are
reported as number of migrated cells counted per well.
Immunoprecipitation and Western blotting
Cells (3 £ 105) were plated in 60 mm diameter dishes. After
adhesion, cells were serum-starved overnight and exposed to
VEGF (20 ng/ml) for 10 min (Cantara et al. 2004). In combi-
nation experiments polyphenols (10 nM) were administered
30 min before VEGF. Cells were then lysed. Supernatant
(5ml) from each lysate was used for protein assay. To evaluate
extracellular signal-regulated kinases 1/2 (ERK1/2) and phos-
phatidylinositol-3 kinase (PI3K)/Akt activation, 30mg
proteins were mixed with 4 £ reducing SDS–PAGE sample
buffer and denatured at 1008C for 10 min. Electrophoresis
was carried out in SDS–10 % polyacrylamide gel. Proteins
were then blotted on to activated nitrocellulose membranes,
incubated overnight with the antibodies (anti-phospho-
ERK1/2 or anti-phospho-Akt) and then detected by an
enhanced chemiluminescence system (Amersham, Milan,
Italy). Results were normalised to those obtained by using
an antibody to total ERK1/2 or actin. For VEGFR-2 acti-
vation, PAEC–VEGFR-2 cells were treated as described ear-
lier and lysed. VEGFR-2 was immunoprecipitated overnight
by using anti-VEGFR-2 antibody. Immunocomplexes were
bound to protein A-Sepharose and washed three times. Immu-
noprecipitates were resolved on SDS–PAGE (8 %) and pro-
teins were transferred to nitrocellulose membranes.
Phosphorylated VEGFR-2 was evidenced by using anti-phos-
pho-tyrosine antibody and the detection system as described
earlier.
Measurement of cGMP levels
cGMP levels were measured on cell extracts from confluent
cell monolayers by enzyme immunoassay kit
(Cayman; Cabru, Milan, Italy). Cell monolayers were treated
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with 1 mM-3-isobutyl-5-methyl-xanthine for 15 min before
stimulation (Cappelli et al. 2004). After stimulation, cells
were rinsed with PBS and removed by scraping in ice-cold
60 % ethanol (v/v). Following ethanol evaporation, cGMP
levels were assayed in the supernatant according to the manu-
facturer’s instructions, while proteins were measured in the
pellet by Bradford’s procedure. Data are expressed as pmol
cGMP per mg protein.
Statistical analysis
Results are expressed as means with their standard errors.
Statistical analysis was performed using Student’s t test and
ANOVA. When a significant difference was detected, multiple
comparison analysis was performed using the
Student–Newman–Keuls test. A value of P,0·05 was con-
sidered to denote statistical significance.
Reagents
Quercetin was purchased from Sigma-Aldrich (Milan, Italy).
Q30S was prepared as described by Day et al. (2001). Q3G
was purified from grape skins (V. vinifera var. Muscat of Fron-
tignan) using the following procedures. Skins were peeled and
extracted with methanol containing 2 % acetic acid during 4 h
at room temperature. After filtration and concentration of the
extract under reduced pressure, purification was achieved by
chromatography on Fractogel TSK HW 50 F. Elution was car-
ried out with water (pH 7) and monitored by HPLC coupled to
a diode array detector and an electrospray ionisation–MS
detector. The fraction containing flavonol glucuronides was
then concentrated and stored at 2208C until freeze-dried.
Final purification was achieved by chromatography on a poly-
amide column followed by HPLC on a C18 column, using a
procedure up-scaled from Cheynier & Rigaud (1986).
Q3G was identified and its purity checked by HPLC–ESI–
MS and NMR analysis. Mass signal at m/z 477 in the negative
ion mode; 1H NMR (500 MHz, dimethyl sulphoxide): d 3·22–
3·35 (2H, m H2-glcA, H3-glcA), 3·39 (1H, dd, 4-glcA), 3·58
(1H, d, J4,5 9·9, 5-glcA), 5·49 (1H, d, J1,2 7·6, 1-glcA), 6·41/
6·21 (2H, d, J6,8 1·7, H6/H8), 6·84 (1H, d, J50,60 8·3, H5
0),
7·60 (1H, dd, J50,60 8·3, J20,50 1·6, H6
0), 7·54 (1H, d, J20,50 1·6,
H20). The position of the glucuronide was confirmed by
heteronuclear multiple bond correlation from long-distance
correlation between the carbon at C3 (133·3 ppm) and the
H1-glcA (5·49 ppm).
A stock solution of 10 mM was prepared in dimethyl sulph-
oxide (free quercetin) or methanol (Q30S and Q3G) and stored
in aliquots at 2808C. Free quercetin was dissolved in metha-
nol for pellet preparation. VEGF was obtained from Peprotech
(Inalco, Milan, Italy). The PI3K inhibitor LY294002,
the mitogen-activated protein kinase kinase inhibitor U0126,
thenitric oxide synthase inhibitor Nv-methyl-L-arginine and
the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-
a ]quinoxalin-1-one were provided by Calbiochem (Inalco,
Milan, Italy). Anti-phospho-ERK1/2, anti-ERK1/2, anti-phos-
pho-Akt and anti-phospho-tyrosine antibodies were obtained
from Cell Signalling (Celbio S.p.A., Milan, Italy). Anti-
VEGFR-2 antibody was from Upstate Biotechnology (DBA,
Milan, Italy). Anti-b-actin was from Sigma-Aldrich.
Results
Quercetin metabolites differentially affect angiogenesis in vivo
We designed experiments to analyse the interaction between
quercetin, its metabolites and VEGF on angiogenesis in the
avascular rabbit cornea. The assay provides integrated infor-
mation on the ability of molecules either to promote new
capillary formation or to influence the response to angiogenic
growth factors (Morbidelli & Ziche, 2004). VEGF (200 ng/
pellet) elicited a florid growth of new capillaries, which devel-
oped during time, and gradually invaded the corneal stroma,
giving an angiogenic score of 6 (Fig. 1(a)). In contrast, neither
quercetin nor its metabolites (tested per se at 1mg/pellet) were
capable of inducing formation of new capillaries (Fig. 1(a)).
No inflammatory responses were observed in these implants.
When quercetin and its metabolites were delivered to the
cornea simultaneously with VEGF, we observed a marked
and significant reduction (P,0·01) of the angiogenic response
to VEGF for free quercetin and its glucuronide metabolite
Q3G (Fig. 1(b–d)). On the contrary, Q30S exerted no inhi-
bition, with a slight not significant potentiation of VEGF
response (Fig. 1(b, c, e)).
Quercetin metabolites exert a dual role on endothelial cell
proliferation and migration
The influence of polyphenols on VEGF-induced formation of
capillaries prompted us to study their effects on CVEC, as the
activation of their basic functions, i.e. proliferation and
migration, which are the prerequisite for the expression of
the angiogenic phenotype. In quiescent endothelial cells
(0·1 % BCS) Q30S induced cell growth (Fig. 2(a)). When
expressed in terms of the response attainable in these cells
with 0·1 % BCS medium, Q30S increased proliferation by
40 % at 1 nM (P,0·01) and 25 % at 1 pM (Fig. 2(a)), being
the proliferative effect of VEGF of 43 (SEM 2) % over basal
response. Both quercetin and its glucuronide exerted no
effect on proliferation at sub-nanomolar concentrations
(Fig. 2(a)).
When cells were induced to grow by exposure to VEGF,
addition of Q30S (1 nM to 1mM range) did not change prolifer-
ation (Fig. 2(b)), while quercetin and its glucuronide conjugate
inhibited the VEGF response. Quercetin inhibited cell prolifer-
ation by 40 % at 1 nM, this concentration being the most effec-
tive. The inhibitory effect elicited by Q3G was significant in
the range 10 nM to 1mM (Fig. 2(b)).
Quercetin metabolites were then tested on cell migration
towards the VEGF gradient. Again quercetin and Q3G, but
not Q30S, significantly inhibited VEGF-induced chemotaxis
(Table 1).
The inhibitory effect of Q3G on endothelial functions was
not due to cytotoxic effects, since neither quercetin metab-
olites nor the corresponding solvents were toxic at the concen-
trations used in the experiments (data not shown).
Thus, quercetin metabolites appeared to exert divergent
actions on cell proliferation and migration in the absence
and in the presence of exogenous VEGF. The sulphate conju-
gate clearly induced replication of unstimulated cells. Under
VEGF stimulation, quercetin and the glucuronide metabolite,
but not the sulphate conjugate, exhibited an inhibitory effect
on cell migration and proliferation.
S. Donnini et al.1018
https:/www.cambridge.org/core/terms. https://doi.org/10.1079/BJN20061753
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 10 Jul 2017 at 15:18:54, subject to the Cambridge Core terms of use, available at
Opposing effects of quercetin metabolites on cell signalling
In light of the results obtained in cultured cells and on angio-
genesis, we investigated signals known to be involved in the
expression of the angiogenic phenotype. ERK1/2 phosphoryl-
ation, a reliable marker of cell activation and proliferation,
increased as a result of VEGF (20 ng/ml) application (Fig. 3).
Quercetin and Q3G (tested at 10 nM) had no effect on basal
ERK1/2 activation. Interestingly, Q30S increased the levels
of phospho-ERK1/2 by 50 % (Fig. 3(a)) and produced a
further not significant increase in VEGF-induced
mitogen-activated protein kinase phosphorylation (Fig. 3(b)).
In contrast, quercetin and Q3G inhibited VEGF-induced
ERK1/2 phosphorylation (Fig. 3(b)).
Molecular mechanisms for the activity of quercetin-3 0-
sulphate on endothelial cells
Since Q30S enhanced ERK1/2 phosphorylation and stimu-
lated endothelial cell activation both in the quiescent state
or when activated by VEGF, we examined whether this
metabolite would interact with VEGF receptor (VEGFR-2)
signalling (Zachary, 2003). Measurement of CVEC prolifer-
ation following challenge with Q30S (or quercetin for com-
parison) in the presence of the PI3K inhibitor LY294002,
the nitric oxide synthase inhibitor N v-methyl-L-arginine,
the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a ]-
quinoxalin-1-one or mitogen-activated protein kinase kinase
inhibitor U0126 showed a distinct pattern of growth inhi-
bition. As illustrated in Fig. 4, exposure to Q30S elicited a
significant proliferation of CVEC above control (P,0·01).
Inhibitors of the VEGFR-2 signalling cascade invariably
reduced the effect of Q30S on cell growth, leaving control
cells or those treated with quercetin (not shown) unaffected
(Fig. 4).
Further analysis of the interaction between Q30S and the
VEGF signalling was performed in PAEC in which the
VEGFR-2 is stably transfected (PAEC–VEGFR-2) by monitor-
ing the phospho-tyrosine residues linked to the receptor. As
expected, VEGF enhanced phosphorylation signalling three-
fold, while concomitant exposure to VEGF and Q30S enhanced
phospho-VEGFR-2 fivefold, indicating a positive interaction of
the metabolite with VEGF signalling (Fig. 5(a)).
Signals downstream of the VEGFR-2, such as PI3K/Akt and
cGMP, were also enhanced in endothelial cells exposed simul-
taneously to VEGF and Q30S, and to Q30S alone, respectively
(Fig. 5(b, c)), reflecting the increased tyrosine phosphorylation
observed earlier.
Collectively, the present findings demonstrate that Q30S, but
not quercetin or Q3G, interacts positively with VEGF receptor
signalling, leading to activation of extracellular signal-regu-
lated kinase and promoting cell growth.
Fig. 1. Quercetin metabolites differentially affect in vivo angiogenesis. The rabbit cornea assay was used to assess the angiogenic effect of quercetin-free agly-
cone (. . .O. . .) and conjugates quercetin-3-glucuronide (Q3G; . . .V. . .) and quercetin-30-sulphate (Q30S; . . .W. . .) per se (–B–, vascular endothelial growth factor
(VEGF)) (a) and on VEGF-induced (tested at 200 ng/pellet) neovascularisation (–B–, VEGF; . . .O. . ., VEGF þ quercetin; . . .V. . ., VEGF þ Q3G; . . .W. . ., VEGF þ
Q30S) (b). For details of procedures, see p. 1017. Values, reported as angiogenic score measured daily, are means (of at least four implants) with their standard
errors depicted by vertical bars. Mean values were significantly different from those of VEGF alone: **P,0·01. (c, d, e) Representative pictures of corneal neovas-
cularization (day 14) induced by VEGF alone (c) and in the presence of Q3G (d) and Q30S (e) (1mg each). Original magnification 18 £ B, *Flash artefacts.
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Discussion
A number of studies have elucidated the biological profile of
quercetin, demonstrating the antioxidant and anti-angiogenic
properties of this flavonol in a variety of experimental systems
(Igura et al. 2001; Fan et al. 2003; Tan et al. 2003). Quercetin
was found to inhibit several steps of angiogenesis, including
proliferation, migration and differentiation of endothelial
cells. The molecular mechanisms described to be inhibited
in endothelial cells by the free aglycone are mitogen-activated
protein kinase, c-Jun NH2-terminal kinase and focal adhesion
kinases (Kobuchi et al. 1999; Kaneider et al. 2004), and
metalloproteinase-2 expression and activity (Tan et al. 2003).
However, following administration of quercetin-rich foods,
the glucuronide and sulphate derivatives of quercetin predomi-
nate. The ratio of these appears to vary according to as yet
unknown factors, but it is clear that only traces of the free
aglycone are found in human plasma (Gee et al. 2000; Day
et al. 2001; O’Leary et al. 2001). This is due to the rapid
and extensive conjugation of quercetin, so that it is assumed
that aglycone is less important in the biological effects
observed in vivo.
In the present study, we found that quercetin conjugates
exhibit divergent effects on the endothelium and on angiogen-
esis. On one hand, Q3G and quercetin itself have no effect, at
least at the concentration examined in the present study, on
quiescent endothelium, while they inhibit endothelial func-
tions and in vivo angiogenesis elicited by VEGF. Consistently,
these compounds reduce mitogen-activated protein kinase
activation, the intracellular signal underlying endothelial acti-
vation. On the other hand, Q30S increases significantly the
growth of quiescent endothelial cells reaching maximal
activity at 1mM, while it has no effect on cell proliferation
stimulated by VEGF. Its actions on in vivo angiogenesis
consist of a small, non-significant enhancement of the
VEGF response. The observed increase of ERK1/2 phos-
phorylation by Q30S is entirely in line with the findings
given earlier.
Exploring further the molecular mechanism for the pro-pro-
liferative effect of Q30S and its partial potentiating effect on
VEGF-induced angiogenesis, we observed that the sulphate
metabolite is able to facilitate the activation of the VEGF
receptor by its ligand and to ignite the intracellular signalling
pathways characteristic of VEGFR-2 activation, including in
the order, the PI3K/Akt pathway and the nitric oxide
synthase/cGMP cascade (Kroll and Waltenberger, 1998; Par-
enti et al. 1998, Zachary, 2003). These signals ultimately con-
verge on mitogen-activated protein kinase activation and
support the synergistic effect of Q30S and VEGF in inducing
an angiogenic phenotype.
Differences in the biological action between quercetin con-
jugates have been noted also in other cells as well as at the
biochemical level. For example, in lymphoblastoid cells,
Q30S prevented H2O2-induced chromosomal damage, while
quercetin did not (Saito et al. 2004). This preventive effect
toward oxidative injury fits with the pro-proliferative action
on the endothelium observed in the present study. Differences
between quercetin conjugates have also been reported in their
ability to inhibit LDL oxidation and albumin binding, with
Q3G a more efficient antioxidant than Q30S (Janisch et al.
2004).
Opposing properties of natural compounds contained in the
same plant have been recently reported. Sengupta et al. (2004)
have described opposing activities of two ginsenosides con-
tained in ginseng, which exert totally different effects on the
angiogenic phenotype. These authors have rationalised their
findings by postulating the existence of a yin–yang paradigm
in this plant.
Fig. 2. Proliferation of capillary endothelial cells is differentially affected by
quercetin metabolites. (a), The effect of increasing concentrations (1 pM to
1mM) of quercetin (–A–), quercetin-30-sulphate (–B–) and quercetin-3-glucur-
onide (–O–). (b), The effect of increasing concentrations (1 nM to 1mM) of
quercetin metabolites on vascular endothelial growth factor-induced (VEGF;
20 ng/ml) proliferation. For details of procedures, see p. 1017. Values are
means (of four experiments run in triplicate) with their standard errors
depicted by vertical bars. Mean values were significantly different from those
of the basal response: **P,0·01. Mean values were significantly different
from those of VEGF alone: *P , 0·05; ††P,0·01; ***P , 0·001.
Table 1. Effect of quercetin metabolites on endothelial cell migration‡
(Mean values with their standard deviations for three experiments run
in triplicate)
No. of migrated cells counted per well
Control VEGF
Compound (10 nm) Mean SEM Mean SEM
None 110 5 138 4*
Quercetin 109 3 122 2†
Q30S 112 1 138 8
Q3G 100 1 100 12†
Q30S, quercetin-30-sulphate; Q3G, quercetin-3-glucuronide; VEGF, vascular endo-
thelial growth factor.
Mean values were significantly different from those of the basal condition:
*P,0·05.
Mean values were significantly different from those of VEGF alone: †P,0·05.
‡ Coronary venular endothelial cells exposed to 10 nM-quercetin metabolites were
challenged for migration toward VEGF (20 ng/ml). Cell migration was monitored
after 4 h incubation. For details of procedures, see p. 1017.
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The changes of either endothelial cell proliferation in
response to VEGF or angiogenic response observed in the pre-
sent study occurs at low concentrations of quercetin metab-
olites, generally in the upper nanomolar range. This is
similar to a range of quercetin metabolites found at peak in
plasma (0·02–4mM) following administration of high-querce-
tin onions to man (de Pascual-Teresa et al. 2004). Moreover,
as shown in the present study, high micromolar concentrations
of these compounds produce fairly severe cell toxicity. This
casts doubt upon the relevance of reported effects by quercetin
on angiogenesis or other systems at high micromolar concen-
trations (usually above 100mM).
In summary, the present study demonstrates the anti-angio-
genic activities of quercetin and its conjugate Q3G on
VEGF-activated endothelium, and the pro-angiogenic property
of Q30S. Thus, the balance of circulating quercetin conjugates
rather than quercetin itself may determine the final effect of
Fig. 4. Vascular endothelial growth factor receptor-2 and its intracellular sig-
nalling are involved in quercetin-30-sulphate-induced (Q30S) proliferation. Cells
were pretreated with 50mM-Ly294002 (B), 100mM N v-methyl-L-arginine (B),
10mM-1H-[1,2,4]oxadiazolo[4,3-a ]quinoxalin-1-one (J) or 10mM-U0126 (p)
for 30 min before the addition of Q30S (10 nM). (A), No pretreatment (0·1 %
bovine calf serum). For details of procedures, see p. 1017. Values are means
(of three experiments) with their standard errors depicted by vertical bars.
Mean values were significantly different from those of Q30S alone: *P,0·05.
Mean values were significantly different from those of the control: **P,0·01.
Fig. 5. Biochemical characterisation of quercetin-30-sulphate (Q30S) pro-
angiogenic effect. (a), Serum-starved semi-confluent porcine aortic endothelial
cells overexpressing vascular endothelial growth factor receptor-2 (VEGFR-2)
were stimulated for 5 min with 20 ng/ml vascular endothelial growth factor
(VEGF) in the absence and in the presence of quercetin (Q) and Q30S (10 nM,
30 min pretreatment). Lysates were immunoprecipitated with anti-VEGFR-2
antibody. The immunoprecipitated proteins were collected, resolved on
SDS–PAGE, transferred to nitrocellulose membrane and immunoblotted with
an anti-phospho-tyrosine antibody (2pVEGFR-2). A representative blot is
shown. Optical density (OD) values are means (of three gels) with their stan-
dard errors. (b) Phospho-Akt (pAkt) was evaluated by Western blotting of cor-
onary venular endothelial cells (CVEC) lysates. Blots are representative of
four experiments with similar results. Membranes were reprobed with anti-
actin antibody for protein level. (c), cGMP accumulation following exposure of
CVEC to VEGF or quercetin metabolites for 10 min was measured by enzyme
immunoassay kit. Values are means (of three experiments) with their standard
errors depicted by vertical bars. For details of procedures, see p. 1017. Mean
values were significantly different from those of the control: *P,0·05.
Fig. 3. Effect of quercetin metabolites on extracellular signal-regulated kinases 1/2 (ERK1/2) activation in basal conditions and upon vascular endothelial growth fac-
tor (VEGF) stimulation. (a), Basal ERK1/2 phosphorylation measured after 10 min of incubation with 10 nM of the compounds. (b), VEGF-induced (20 ng/ml) ERK1/2
phosphorylation in the presence of quercetin metabolites (10 nM, 30 min preincubation). For details of procedures, see p. 1017. A representative gel of phospho-
ERK1/2 (upper bands) and total ERK1/2 (lower bands) out of three with similar results is reported. Data have been normalised on total ERK1/2 bands; histogram
values are means (of three experiments) with their standard errors depicted by vertical bars. Mean values were significantly different from those of the control:
**P,0·01. Mean values were significantly different from those of VEGF alone: ††P,0·01. Q, quercetin; Q30S, quercetin-30-sulphate; Q3G, quercetin-3-glucuronide.
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dietary quercetin in vivo. This knowledge, together with infor-
mation on individual variability in the metabolism of querce-
tin, may be useful in interpreting the results of clinical studies.
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